Benzinga | Jun 18, 2021 07:45AM EDT

Deutsche Bank Initiates Coverage On Abiomed with Buy Rating, Announces Price Target of $360

Deutsche Bank analyst Pito Chickering initiates coverage on Abiomed (NASDAQ:ABMD) with a Buy rating and announces Price Target of $360.